Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Exclusion Criteria

• •1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
• •2. Receipt of any vaccination (including influenza) within 4 weeks of screening visit
• •3. History of blood donation within 2 months of screening visit
• •4. History of anaphylaxis to any LH-RH analogues
• •5. Receipt of any LHRH suppressive therapy within 6 months of screening visit
• •6. Major surgery, including any prostatic surgery, within 4 weeks of screening visit
• •7. History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases and subjects at risk for spinal cord compression
• •8. Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
• •9. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
• •10. History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
• •11. Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
• •12. History of drug and/or alcohol abuse within 6 months of Baseline
• •13. Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
• •14. Use of 5-alpha reductase inhibitor within the last 6 months of screening visit
• •15. History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac \> 9.5% or urine glycosuria \> 1.0 g/dL should be excluded.
• •16. Use of systemic corticosteroids at a dose \>10 mg/d or anti-androgens
• •17. Use of any investigational agent within 4 weeks of screening visit
• •18. Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except for those listed in the permitted Concomitant Treatment section.
• •19. Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor